tert-butyl ((3,5-dichlorophenylsulphonyl)-{5-[3-(morpholin-4-ylcarbonyl)benzylaminocarbonyl]naphthalen-1-yl}amino)acetate | 1192207-09-2

• 分子结构分类: 有机化合物 - 苯类化合物
• 英文名称: tert-butyl ((3,5-dichlorophenylsulphonyl)-{5-[3-(morpholin-4-ylcarbonyl)benzylaminocarbonyl]naphthalen-1-yl}amino)acetate
• 英文别名: Tert-butyl 2-[(3,5-dichlorophenyl)sulfonyl-[5-[[3-(morpholine-4-carbonyl)phenyl]methylcarbamoyl]naphthalen-1-yl]amino]acetate
• CAS: 1192207-09-2
• 化学式: C₃₅H₃₅Cl₂N₃O₇S
• 分子量: 712.651
• InChiKey: YSTVGPQLFABMGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  48
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  131
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS<br/>[FR] NOUVEAUX DÉRIVÉS D'ARYLSULFONYLGLYCINE, LEUR FABRICATION ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009127723A1

  公开（公告）日：2009-10-22

  The invention relates to substituted arylsulphonylglycine derivatives of general formula (I) wherein the groups Ra to Rf, A and Z are defined as in the specification and claims, which are suitable for preparing a pharmaceutical composition for the treatment of metabolic disorders, particularly type 1 or type 2 diabetes mellitus.

  这项发明涉及通式（I）中取代芳基磺酰甘氨酸衍生物，其中基团Ra至Rf、A和Z的定义如规范和索赔中所述，适用于制备用于治疗代谢紊乱，特别是1型或2型糖尿病的药物组合物。
• ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS
  申请人：Langkopf Elke

  公开号：US20110269761A1

  公开（公告）日：2011-11-03

  The invention relates to substituted aryl-sulphonylglycine derivatives of general formula (I) wherein the groups R a to R f , A and Z are defined as in the specification and claims, which are suitable for preparing a pharmaceutical composition for the treatment of metabolic disorders, particularly type 1 or type 2 diabetes mellitus.

  本发明涉及一种通式（I）的取代芳基磺酰基甘氨酸衍生物，其中基团R至Rf、A和Z的定义如规范和要求中所述，适用于制备治疗代谢性疾病，特别是1型或2型糖尿病的药物组合物。